The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine

In the Phase III OptiTROP-Lung06 interim analysis, sac-TMT plus pembrolizumab reduced the risk of progression or death by 51% versus platinum-based chemotherapy plus pembrolizumab (PFS HR 0.49; median PFS 15.0 vs. 5.7 months) in first-line, PD-L1-negative advanced non-squamous NSCLC. Median duration of response was 13.6 vs. 6.8 months, while overall survival showed a favorable trend (HR 0.58; median OS not reached in either group). The 455-patient study met its primary PFS endpoint, with no new safety signals reported; the findings were presented at ESMO and published in The New England Journal of Medicine.

Analysis

The strategic value is greater than the immediate earnings value for Merck (MRK): sac-TMT could strengthen pembrolizumab’s role in first-line NSCLC by replacing the chemotherapy component while keeping Keytruda in the regimen. That may help defend treatment relevance and create lifecycle optionality, but the commercial value to MRK is unquantifiable without the license economics, launch rights by territory, and expected pricing. Kelun-Biotech retains Greater China rights, so the direct regional sales benefit is not MRK’s.

The key clinical distinction is improved disease control without a comparably large gap in response rates; if replicated, that could support durable use, but it does not establish an overall-survival benefit. OS is immature, follow-up is short, and this is a defined PD-L1-negative, driver-negative population—not a read-through to all NSCLC. The result is a credible competitive signal for other ADC-plus-checkpoint-inhibitor programs, raising the bar for alternatives, but not yet a proven new standard or a basis for broad revenue forecasts.

Near term, expect more impact on pipeline probability than MRK estimates. Over 1–3 months, watch full conference data, regulatory plans, and MRK’s disclosures on global development and economics. Over 6–18 months, pivotal read-through and approvals could establish whether the regimen expands Keytruda’s use; safety, manufacturing capacity, pricing, and competing ADC combinations remain execution risks. The thesis weakens if later OS results fail to confirm benefit, regulators require additional evidence, or MRK’s disclosed economics show limited participation.

Key Decisions for Investors

• Do not make a standalone MRK trade on this release: treat it as incremental pipeline/lifecycle support, not a material near-term earnings revision. Reassess if MRK quantifies its economics or identifies a meaningful global commercialization role.
• Add sac-TMT plus pembrolizumab to the NSCLC competitive watchlist; verify the full data, subsequent OS maturity, regulatory filing timing, and whether the regimen is intended to replace chemotherapy or carry a distinct treatment positioning.
• Track competing ADC–checkpoint inhibitor trial readouts over the next 6–18 months. A replicated PFS advantage with acceptable safety could pressure competing regimens; failure to confirm survival benefit or emerging tolerability/manufacturing constraints would falsify the bullish adoption case.
• For Kelun-Biotech, distinguish Greater China commercial upside from ex-China value licensed to MSD; do not capitalize the global opportunity without the royalty, milestone, and cost-sharing terms.